Autres langues Cardiol Therapeutics Inc.

Actions

CRDL

CA14161Y2006

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
2,370 ^CAD	-1,66%		-4,82%	+80,92%

23/09	Cardiol Therapeutics atteint l’objectif de recrutement de l’étude MAVERIC de phase III en avance et élargit l’essai pivot	CI
23/09	Cardiol Therapeutics Inc. atteint l’objectif d’inclusions de MAVERIC et étend l’essai pivot évaluant CardiolRx	CI

Autres langues

23/09	Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead of Schedule and Expands Pivotal Trial
23/09	Cardiol Therapeutics : Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s Efficacy
23/09	Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
23/09	Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
23/09	Cardiol Therapeutics Inc. Achieves MAVERIC Enrollment Target And Expands Pivotal Trial Evaluating CardiolRx
16/09	Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
16/09	Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
10/09	Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
10/09	Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
09/09	Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
09/09	Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
12/08	Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
05/08	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
14/07	Cardiol Therapeutics : rsquo; Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
14/07	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
14/07	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
09/07	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
09/07	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
25/06	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
25/06	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
23/06	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
23/06	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
14/05	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
14/05	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ